Developed by GlaxoSmithKline (GSK), Jemperli belongs to the class of immune checkpoint inhibitors that target the PD-1 receptor on T-cells. By blocking this pathway, it prevents cancer cells from evading immune detection, allowing T-cells to identify and destroy them more effectively. https://www.drugsgeneral.com/jemperli-injection/